Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China National Biotec Group To Offload Non-Performing Assets

This article was originally published in PharmAsia News

Executive Summary

State-owned China National Biotec Group is gradually offloading its non-performing subsidiaries and those without controlling rights. According to Shanghai United Assets and Equity Exchange, the enterprise has put its wholly owned Tangshan subsidiary on the market for RMB 490,000. Meanwhile, Wuhan Institute of Biologic Products, one of CNBG's six major institutions, will transfer its 30 percent stake in Zhongwei Biotech Company for RMB 510,000. Analysts observe that the move is a prelude to the group's asset clearance and paves the way for its restructuring before going public. Beijing Tiantan Biological Products, CNBG's only listing platform, currently has 51 percent of Changchun Keygen Biological Products and the entire Chengdu Institute of Biological Products. Tiantan is expected to take over Wuhan Institute next. (Click here for more - Chinese Language)

You may also be interested in...



Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims

Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.

UsernamePublicRestriction

Register

SC143429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel